

Table A2 Checkmate 649 results from subgroup analysis by PD-L1 CPS: Three year follow up²⁴.

Population	Nivolumab + chemotherapy	Chemotherapy alone	Unstratified HR (95% CI)	Comment
Median overall survival (months)				
Overall (n = 1581)	13.8	11.6	0.79 (0.70-0.89)	Favours combination
PD-L1 CPS < 1 (n = 265)	13.1	12.5	0.95 (0.74-1.24)	NS
PD-L1 CPS ≥ 1 (n = 1297)	13.8	11.3	0.75 (0.66-1.124)	Favours combination
PD-L1 CPS < 5 (n = 607)	12.4	12.3	0.95 (0.80-1.12)	NS
PD-L1 CPS ≥ 5 (n = 955)	14.4	11.1	0.69 (0.60-0.79)	Favours combination
Objective response rate (%)				
Overall (n = 1209)	58	46	12 (6-17.7)	NR
PD-L1 CPS < 1 (n = 179)	51	41	10 (-4.7 to 23.8)	NS
PD-L1 CPS ≥ 1 (n = 1016)	60	46	13 (7 – 19.2)	Favours combination
PD-L1 CPS < 5 (n = 427)	56	46	9 (-0.4 – 18.3)	NS
PD-L1 CPS ≥ 5 (n = 768)	60	45	15 (7.6 – 21.5)	Favours combination

CI: confidence interval; HR: hazard ratio; NS: not significant

P values not reported for 3-year follow up.

PFS not reported for all CPS sub-groups for 3-year follow up.